AU743102B2 - Pharmaceutical substance containing various vitamin K-dependent factors - Google Patents

Pharmaceutical substance containing various vitamin K-dependent factors Download PDF

Info

Publication number
AU743102B2
AU743102B2 AU92449/98A AU9244998A AU743102B2 AU 743102 B2 AU743102 B2 AU 743102B2 AU 92449/98 A AU92449/98 A AU 92449/98A AU 9244998 A AU9244998 A AU 9244998A AU 743102 B2 AU743102 B2 AU 743102B2
Authority
AU
Australia
Prior art keywords
factor
preparation according
protein
preparation
factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU92449/98A
Other languages
English (en)
Other versions
AU9244998A (en
Inventor
Yendra Linnau
Hans Peter Schwarz
Peter Turecek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter AG filed Critical Baxter AG
Publication of AU9244998A publication Critical patent/AU9244998A/en
Application granted granted Critical
Publication of AU743102B2 publication Critical patent/AU743102B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU92449/98A 1997-09-19 1998-09-17 Pharmaceutical substance containing various vitamin K-dependent factors Ceased AU743102B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0159197A AT409334B (de) 1997-09-19 1997-09-19 Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
AT1591/97 1997-09-19
PCT/AT1998/000224 WO1999015196A1 (de) 1997-09-19 1998-09-17 Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren

Publications (2)

Publication Number Publication Date
AU9244998A AU9244998A (en) 1999-04-12
AU743102B2 true AU743102B2 (en) 2002-01-17

Family

ID=3516739

Family Applications (1)

Application Number Title Priority Date Filing Date
AU92449/98A Ceased AU743102B2 (en) 1997-09-19 1998-09-17 Pharmaceutical substance containing various vitamin K-dependent factors

Country Status (10)

Country Link
EP (1) EP1015020A1 (no)
JP (1) JP2001517636A (no)
AT (1) AT409334B (no)
AU (1) AU743102B2 (no)
BR (1) BR9812222A (no)
CA (1) CA2304396A1 (no)
HU (1) HUP0003681A1 (no)
NO (1) NO20001415L (no)
SK (1) SK4022000A3 (no)
WO (1) WO1999015196A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2470511C (en) 2001-12-21 2014-05-27 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
EP1485121A4 (en) * 2002-03-08 2007-11-07 Lilly Co Eli ACTIVE C PROTEIN FORMULATIONS
ES2523655T5 (es) 2002-06-21 2018-04-23 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
WO2004103398A1 (en) 2003-05-23 2004-12-02 Novo Nordisk Health Care Ag Protein stabilization in solution
JP4658041B2 (ja) 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
MXPA06001698A (es) 2003-08-14 2006-05-19 Novo Nordisk Healthcare Ag Composicion farmaceutica liquida y acuosa de polipetidos de factor vii.
EP3378470A1 (en) 2003-12-19 2018-09-26 Novo Nordisk Health Care AG Stabilised compositions of factor vii polypeptides
WO2006088741A2 (en) * 2005-02-16 2006-08-24 The Board Of Trustees Of The University Of Illinois Procoagulants based on metal-chelating lipids
WO2006096345A2 (en) 2005-03-04 2006-09-14 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
WO2009046194A2 (en) 2007-10-05 2009-04-09 The Board Of Trustees Of The University Of Illinois Fibrin sealant
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
KR20120108989A (ko) 2009-12-18 2012-10-05 시에스엘 리미티드 폴리펩타이드를 정제하는 방법
JP6000259B2 (ja) * 2010-10-06 2016-09-28 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 止血障害治療用第ｉｉ因子およびフィブリノーゲン
PL3579857T3 (pl) * 2017-02-09 2022-07-25 Csl Behring Gmbh Produkt zastępujący czynnik krzepnięcia krwi do stosowania w leczeniu lub profilaktyce krwawień

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0617049A1 (en) * 1992-03-22 1994-09-28 SCLAVO S.p.A. Process for the isolation of highly purified factors IX, X and II from prothrombin complex or human plasma
EP0700684A2 (de) * 1994-08-26 1996-03-13 BEHRINGWERKE Aktiengesellschaft Zusammensetzungen, enthaltend Prothrombinkomplex-Konzentrat und wenigstens eine weitere Komponente das die Blutgerrinnung fördert, als Gegenmittel für Blut-Anticoagulanzien

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729822D0 (en) * 1987-12-22 1988-02-03 Central Blood Lab Authority Chemical process
DE4342132C1 (de) * 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
ES2241030T3 (es) * 1996-03-20 2005-10-16 Baxter Aktiengesellschaft Preparado farmaceutico para el tratamiento de alteraciones de la coagulacion sanguinea.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0617049A1 (en) * 1992-03-22 1994-09-28 SCLAVO S.p.A. Process for the isolation of highly purified factors IX, X and II from prothrombin complex or human plasma
EP0700684A2 (de) * 1994-08-26 1996-03-13 BEHRINGWERKE Aktiengesellschaft Zusammensetzungen, enthaltend Prothrombinkomplex-Konzentrat und wenigstens eine weitere Komponente das die Blutgerrinnung fördert, als Gegenmittel für Blut-Anticoagulanzien

Also Published As

Publication number Publication date
EP1015020A1 (de) 2000-07-05
NO20001415D0 (no) 2000-03-17
AU9244998A (en) 1999-04-12
JP2001517636A (ja) 2001-10-09
NO20001415L (no) 2000-05-19
SK4022000A3 (en) 2000-09-12
AT409334B (de) 2002-07-25
ATA159197A (de) 2001-12-15
HUP0003681A1 (hu) 2001-02-28
WO1999015196A1 (de) 1999-04-01
CA2304396A1 (en) 1999-04-01
BR9812222A (pt) 2000-07-18

Similar Documents

Publication Publication Date Title
US5457181A (en) Preparation of a high-purity human factor IX concentrate and other plasmatic proteins and their therapeutic use
JP3330932B2 (ja) 抗凝固剤タンパク質
US5344918A (en) Process for the manufacture of a high-purity activated factor VII concentrate essentially free of vitamin K-dependent factors and factors VIIIC and VIIICAg
Kisiel et al. [26] Protein C
AU743102B2 (en) Pharmaceutical substance containing various vitamin K-dependent factors
US5478558A (en) Method of dissolving venous Thrombi using drug containing activated Protein C
AU630477B2 (en) Factor xa based anticoagulant compositions
CA2200394A1 (en) A pharmaceutical preparation for treating blood coagulation disorders
JP2002518411A (ja) 薬学的第ｖｉｉ因子調製物
EP0607392B1 (en) Plasma fraction purification
Michalski et al. Large‐scale production and properties of a solvent‐detergent‐treated factor IX concentrate from human plasma
US6063909A (en) Preparation of factor IX
US6034222A (en) Method for the separation of recombinant pro-factor IX from recombinant factor IX
JPH1059866A (ja) 血液凝固第ｖｉｉ因子及び／もしくは活性化血液凝固第ｖｉｉ因子の製造方法
EP0139447B1 (en) A process for preparing urokinase zymogen
US6403556B1 (en) Pharmaceutical preparation containing protein C and a thrombolytically active substance
US20060147441A1 (en) Plasminogen fragment having activity to inhibit tumor metastasis and growth and process for preparing same technical field
MXPA00002622A (es) Preparado farmaceutico que contiene factores individuales dependientes de la vitamina k
Andersson Purification and studies of components of the haemostatic system by affinity chromatography
CZ2000982A3 (cs) Farmaceutický preparát obsahující jednotlivé faktory, závislé na vitaminu K a jeho použití
Neal et al. The role of factor VIII in blood coagulation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired